Director Trades
A millennial director put his $100k into his own company rather than a house deposit It was millionaire’s row last week in small cap land, with four multi-million dollar trades and one that was pretty close…
Health & Biotech
Health & Biotech
The biotech veteran chasing a billion-dollar pot of gold He was famously worth over $130 million — on paper at least — when he was running Chemeq, which blew itsel up a decade ago after he left.
Health & Biotech
Health & Biotech
Why this 29-year-old investor took a six-figure stake in a $17m biotech company I prefer to have my money be working for me,” he tells Stockhead. “I don’t want it to be at the beck and call of Trump having…
Sky Business News
Sky Business News
Interview with Peter Switzer One of the worrying trends in hospitals are superbugs, raising question marks over the efficacy of antibiotics. Listed company Recce target is targeting this issue ..
S&P Global
S&P Global
Small companies play big role in search for superbug killers Superbugs are quickly becoming a top health concern, yet there has been a roughly 30-year dry spell in antibiotic molecule discovery…
The West Australian
The West Australian
WA tests synthetic antibiotic A Perth-based pharmaceutical research company is a step closer to developing a new class of synthetic antibiotics to overcome superbugs. Recce Limited has started …
The Australian
The Australian
Australia’s Recce strives for immune-proof super-antibiotic Introductory offers to be billed as follows: The Australian Digital Subscription costs 50c per day, billed monthly (min cost up…
BioWorld
BioWorld
Recce nears clinic with ‘master key’ antibiotic to take on superbugs PERTH, Australia – A new class of synthetic antibiotics with broad-spectrum activity is being developed by Sydney-based…
Fighting Antibiotic Resistance
Fighting Antibiotic Resistance
The world needs new classes of antibiotics Antibiotics
The world needs new classes of antibiotics Antibiotics are used as our frontline treatment…
Nature Biopharma
Nature Biopharma
New class of synthetic antibiotics set to tackle superbugs PERTH, Australia – A new class of synthetic antibiotics with broad-spectrum activity is being developed by Sydney-based…